Congratulations to Par portfolio company, Cumulus Neuroscience which has completed patient enrolment in its ground-breaking clinical study, CNS-101.
This clinical trial will enable participants with early-stage Alzheimer’s disease to undertake the study remotely in real-world settings, thanks to Cumulus’ FDA cleared EEG headset and the Cumulus digital platform, rather than having to attend specialist test centres for surveillance. Bringing clinical trials to the patient and removing the need for a clinical setting has the potential to rapidly increase the speed of development of new drugs targeting degenerative neurological diseases, such as Alzhemier’s.
The trial will be led by the University of Cambridge and University of Oxfordwith full results to be presented in early 2024.”
Aman H. Bhatti, MD, Brian Murphy, Tina Sampath,
Ruth McKernan, Prof. Simon Best OBE FRSE